Literature DB >> 28118923

Computer-aided assessment of the generalizability of clinical trial results.

Amos Cahan1, Sorel Cahan2, James J Cimino3.   

Abstract

BACKGROUND: The effects of an intervention on patients from populations other than that included in a trial may vary as a result of differences in population features, treatment administration, or general setting. Determining the generalizability of a trial to a target population is important in clinical decision making at both the individual practitioner and policy-making levels. However, awareness to the challenges associated with the assessment of generalizability of trials is low and tools to facilitate such assessment are lacking.
METHODS: We review the main factors affecting the generalizability of a clinical trial results beyond the trial population. We then propose a framework for a standardized evaluation of parameters relevant to determining the external validity of clinical trials to produce a "generalizability score". We then apply this framework to populations of patients with heart failure included in trials, cohorts and registries to demonstrate the use of the generalizability score and its graphic representation along three dimensions: participants' demographics, their clinical profile and intervention setting. We use the generalizability score to compare a single trial to multiple "target" clinical scenarios. Additionally, we present the generalizability score of several studies with regard to a single "target" population.
RESULTS: Similarity indices vary considerably between trials and target population, but inconsistent reporting of participant characteristics limit head-to-head comparisons.
CONCLUSION: We discuss the challenges involved in performing automatic assessment of trial generalizability at scale and propose the adoption of a standard format for reporting the characteristics of trial participants to enable better interpretation of their results.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trials; Decision support; External validity; Generalizability; Similarity assessment

Mesh:

Year:  2017        PMID: 28118923     DOI: 10.1016/j.ijmedinf.2016.12.008

Source DB:  PubMed          Journal:  Int J Med Inform        ISSN: 1386-5056            Impact factor:   4.046


  6 in total

1.  Comparing and Contrasting A Priori and A Posteriori Generalizability Assessment of Clinical Trials on Type 2 Diabetes Mellitus.

Authors:  Zhe He; Arturo Gonzalez-Izquierdo; Spiros Denaxas; Andrei Sura; Yi Guo; William R Hogan; Elizabeth Shenkman; Jiang Bian
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  A data-zone scoring system to assess the generalizability of clinical trial results to individual patients.

Authors:  Luke J Laffin; Stephanie A Besser; Francis J Alenghat
Journal:  Eur J Prev Cardiol       Date:  2018-11-26       Impact factor: 7.804

3.  A Framework for Systematic Assessment of Clinical Trial Population Representativeness Using Electronic Health Records Data.

Authors:  Yingcheng Sun; Alex Butler; Ibrahim Diallo; Jae Hyun Kim; Casey Ta; James R Rogers; Hao Liu; Chunhua Weng
Journal:  Appl Clin Inform       Date:  2021-09-08       Impact factor: 2.762

4.  Diagnostic Assessment of Assumptions for External Validity: An Example Using Data in Metastatic Colorectal Cancer.

Authors:  Michael A Webster-Clark; Hanna K Sanoff; Til Stürmer; Sharon Peacock Hinton; Jennifer L Lund
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

Review 5.  Clinical Trial Generalizability Assessment in the Big Data Era: A Review.

Authors:  Zhe He; Xiang Tang; Xi Yang; Yi Guo; Thomas J George; Neil Charness; Kelsa Bartley Quan Hem; William Hogan; Jiang Bian
Journal:  Clin Transl Sci       Date:  2020-04-10       Impact factor: 4.689

6.  Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Authors:  Kristina S Boye; Matthew C Riddle; Hertzel C Gerstein; Reema Mody; Luis-Emilio Garcia-Perez; Chrisanthi A Karanikas; Maureen J Lage; Jeffrey S Riesmeyer; Mark C Lakshmanan
Journal:  Diabetes Obes Metab       Date:  2019-03-12       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.